RxDoctor Payments Data

Sarah King

Optometrist · Berea, KYNPI 1447505532

Payments from drug & device makers

$2,507in general payments, 2019–2025

Across 108 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Sun Pharmaceutical Industries Inc.$439
  • Tarsus Pharmaceuticals, Inc.$210
  • Alcon$116
  • Coopervision Inc.$48
  • Oyster Point Pharma, Inc.$43
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$2,507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,507 in reported general payments places this provider in the 75th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,074
Medicare patients
156
Services billed
2,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast97$135,552
RestasisCyclosporine55$62,116
XdemvyLotilaner21$39,508
CequaCyclosporine12$13,801
Cyclosporine13$6,103
Prednisolone Acetate220$5,542
Latanoprost271$2,167
Timolol Maleate114$1,771
Brimonidine Tartrate50$1,344
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha81$877
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat72$829
Difluprednate13$621
Dorzolamide Hcl16$282
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$141
Ofloxacin12$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$210$39,50821 claims
Sun Pharmaceutical Industries Inc.Cequa$439$13,80112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Berea

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →